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NAB would have great utility for the enrichment of AD clinical trials, including large-scale preven-
tion trials.
Methods: Nontargeted proteomic discovery was applied to 78 subjects from the Australian Imaging,
Biomarkers and Lifestyle Flagship Study of Ageing with a range of NAB values. Technical and in-
dependent replications were performed by immunoassay.
Results: Seventeen discovery candidates were selected for technical replication. a2-Macroglobulin,
fibrinogen g-chain (FGG), and complement factor H-related protein 1 were confirmed to be associ-
ated with NAB. In an independent cohort, FGG plasma levels combined with age predicted NAB had
a sensitivity of 59% and specificity of 78%.
Conclusion: A single blood protein, FGG, combined with age, was shown to relate to NAB and
therefore could have potential for enrichment of clinical trial populations.
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The diagnosis of Alzheimer’s disease (AD) can only be
confirmed, with certainty, by histologic examination of the
brain tissue at autopsy. This inspection should demonstrate
considerable evidence of the classic pathologic hallmarks
of AD: extracellular amyloid b (Ab) plaques and intracel-
lular neurofibrillary tangles predominantly composed ofhis is an open access article under the CC BY-NC-ND license (http://
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ease usually affecting people older than age 65, it is believed
the accumulation of Ab plaques begins 15 to 20 years before
clinical presentation [2] and reaches a plateau when cogni-
tive, functional, and behavioral decline occurs [3]. The exist-
ing treatments of AD are only capable of temporary
symptomatic relief in a subset of patients [4]. Because
elevated brain Ab is an important risk factor for eventual
AD, it has become critical to identify individuals at the early
stages of Ab deposition to recruit into clinical trials of poten-
tially disease-modifying therapeutic agents. Three preven-
tion trials of asymptomatic individuals at the early stages
of Ab deposition have recently begun [5].
At present, neuroimaging and cerebrospinal fluid bio-
markers are the accepted standards used to provide evidence
of ongoing AD pathophysiology related to Ab plaques [6].
11C-Pittsburgh compound B (PiB), coupled with positron
emission tomography (PET), is widely used in research in
measuring in vivo Ab deposition, because its uptake in AD
correlates with Ab plaques measured neuropathologically
in the same brains [7]. The availability of longer lived [18]
F- labeled Ab PET tracers, such as flutemetamol [8] and flor-
betapir [9] could foster wider usage in the clinic [10]. Early
“proof of concept” PiB-PET studies demonstrated an in-
crease of Ab deposition in most individuals clinically diag-
nosed with AD, as judged by visual assessment [11] or
quantification of tracer uptake [6,12]. Two large studies,
from Victoria (Australia) and the University of California,
San Francisco, Memory and Aging Center (UCSF), have
shown that PiB-PET could discriminate between AD and
non-Ab dementia [6,13]. Some, but not all [14,15], studies
have also shown that amyloid deposition as measured
using PiB-PET either predicts a decline in cognitive mea-
sures or tracks with such declines [2,16].
Many disease-modifying therapeutic agents being devel-
oped target amyloid generation, deposition, or clearance
[17]. Recent phase III trials targeting amyloid have reported
that approximately 20% of trial participants actually had lit-
tle or no Abwhen studied later using such PET imaging (sus-
pected nonamyloid pathologic findings) [18]. This is a very
serious problem for such trials—success is hard to find in the
field of neurodegeneration but likely to be significantly more
difficult when a large minority of trial subjects fail to have
the primary target pathologic entity.
A solution is to use amyloid-PET scans (w$3000 per
scan) to ensure the presence of the primary target pathologic
entity. The first study to use this will be the Anti Amyloid in
Asymptomatic AD (A4; n 5 1000) prevention trial. In A4,
the screen failure rate is anticipated to be even greater
(w66%) owing to the use of asymptomatic subjects. The
great expense of the anticipated w20% and w66%
amyloid-PET screen failure rates for clinical and prevention
anti-amyloid trials means that a blood test with even rela-
tively low predictive accuracy for neocortical amyloid
burden (NAB) has the potential to greatly reduce costs.
This would work by applying the blood tests to largenumbers of potentially eligible subjects and only performing
PET scans on those whose blood test results are positive.
This would reduce the screen failure rates and save money
if the blood test was comparatively inexpensive. Therefore,
a blood-based measure that correlates with the NAB would
be of considerable value as an enrichment filter for clinical
trials.
The obvious blood candidate biomarker of brain Ab pa-
thology would be Ab itself. A systematic review of the pub-
lished data andmeta-analysis byKoyama et al. [19] of 10,303
subjects found that lower plasma Ab42/Ab40 ratios were
significantly associated with the development of AD. How-
ever, the estimates had wide confidence intervals because
of the high interstudy differences. As such, plasma Ab42/
Ab40 ratios are unlikely to be useful by themselves for the
prediction of NAB. The same study found that the individual
Ab42 and Ab40 levels in blood were not significantly associ-
ated with AD. Clearly, novel biomarkers are needed that
reflect the brain amyloid pathologic features in the blood.
There has been considerable effort in the search for AD
blood-based biomarkers. Most studies have used a case-
control design, with a clinical diagnosis of AD, determined
by the medical history, cognitive assessment findings, and
clinical examination results. This classic, case versus age-
matched controls approach has identified a large number
of putative plasma biomarkers [20–22]. However, such
approaches are intrinsically flawed in the context of
AD, because a considerable proportion of cognitively
unimpaired controls will be in the prodromal phase of AD
(e.g., asymptomatic but with elevated NAB).
An approach to overcome this is to use a nonapparent
measure of disease activity (endophenotype paradigm).
The endophenotype approach is increasingly being adopted,
for example, to study blood-based biomarkers of cognitive
decline [23,24], apolipoprotein E ε4 (APOE ε4) carrier
status [25], brain atrophy [26,27], and hippocampal
metabolism [28]. More recently, blood-based biomarkers
of NAB, as measured by PiB-PET, have been reported
[29–31]. Both Kiddle et al. [30] and Burnham et al. [31]
used the Rules Based Medicine panel of 190 analytes to
discover plasma proteins related to NAB and proposed a
13- and 5-analyte model, respectively. These models both
contained the protein pancreatic polypeptide.
In a different approach, Thambisetty et al. [29] used two-
dimensional gel electrophoresis (2D-GE), coupled with
mass spectrometry (MS), to identify protein spots associating
withNAB in an unbiased fashion. That study identified 6 pro-
teins for spots associated with NAB, including APOE and
complement C3, which were independently replicated in
the study by Kiddle et al. [30]. 2D-GE is a well-established
technique for blood biomarker research and offers many ad-
vantages. However, it is restricted by the lengthy procedure
with poor reproducibility that can only identify a small num-
ber of “candidate spots” in limited sample sets.
In the present study, we used a method that combines
the unbiased approach of gel-based proteomics with
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instrumentation. This has enabled the identification and
quantification of several hundred proteins, comparable to
some panel-based arrays, without losing the key advantages
of unbiased gel-based discovery. This is the first application
of this approach to identify blood-based biomarkers of NAB
and was applied to a subset of patients from the Australian
Imaging, Biomarkers and Lifestyle Flagship Study of
Ageing (AIBL) cohort with either high or low NAB. Prom-
isingmarkers were then replicated using immunoassays, first
in the same cohort and then in an independent cohort [13].2. Material and methods
2.1. Australian Imaging, Biomarkers and Lifestyle
Flagship Study of Ageing
The AIBL study is a longitudinal study of ageing, neuro-
imaging, biomarkers, lifestyle, and clinical and neuropsy-
chological analysis, with a focus on early detection and
lifestyle intervention (available at: http://www.aibl.csiro.
au/). Additional specifics regarding subject recruitment,
diagnosis, and study design have been previously described
[32].2.2. Discovery cohort: assessments, blood collection, and
processing
We examined the plasma samples from a subset of 78
subjects from the AIBL study, who had undergone PiB-
PET scans. A standardized uptake value ratio (SUVR) cutoff
of 1.3 was used to classify subjects as belonging to the PiB1
and PiB2 groups. To increase the statistical power, the sub-
jects were selected to be enriched for clear cases of PiB
negativity and positivity. The standardized clinical assess-
ments included the Mini-Mental State Examination, and
APOE genotypes were available.
The details of blood collection and sample processing
have been previously reported [31]. Plasma proteomic anal-
ysis and immunoassay measures were undertaken at King’s
College London.2.3. AIBL PiB-PET methods
The PiB imaging method of the AIBL study has been pre-
viously reported [33]. SUVRswere generated using the cere-
bellar gray matter as the reference region, as described in the
study by Burnham et al. [31]. NAB was expressed as the
average SUVR of the mean of the frontal, superior parietal,
lateral temporal, lateral occipital, and anterior and posterior
cingulate regions.2.4. Tandem mass tag protein labeling, enzymatic
digestion, and peptide extraction
Each sample was randomly assigned and labeled with an
amine-reactive tandem mass tag (TMT) reagent (TMT127-TMT131; catalog no. 90064, Thermo Scientific), with
TMT126 used to label the study reference, an equal pool
of the plasma obtained from all 78 subjects. A complete
TMT6Plex combined five labeled plasma samples with a
labeled study reference. In general, sample preparation and
TMT labeling was performed as previously described
[23,34], with some minor modifications (see Supplemental
Methods 1, available online). Each TMT6Plex underwent
one-dimensional gel electrophoresis and excised into 10
fractions (see Supplemental Methods 2, available online).
The gel pieces were then destained and digested and the pep-
tides extracted and lyophilized to completion before MS
analysis (Supplemental Methods 3, available online). Liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
data separated with one-dimensional GE can show a single
protein in multiple fractions. Therefore, identical protein
identifications observed in different fractions were consid-
ered as separate entities defined as protein molecular weight
(MW) isoforms (see Supplemental Methods 5b, available
online).2.5. LC-MS/MS data acquisition
The samples were analyzed using an LTQ Orbitrap Ve-
los instrument (Thermo Scientific) coupled to a Proxeon
EASY-nLC II system (Thermo Scientific). Additional de-
tails on chromatographic separation and MS data acquisi-
tion are outlined in Supplemental Methods 4 (available
online).2.6. Preprocessing of LC-MS/MS data
Raw data files produced in Excalibur software (Thermo
Scientific) were processed using Proteome Discoverer,
version 1.3 (Thermo Scientific) to determine peptide identi-
fication; the subsequent Mascot (version 2.3; available at:
http://www.matrixscience.com) output file was used for
additional preprocessing and analysis (see Supplemental
Methods 5a, available online). A script was written in R to
complete the preprocessing, taking into account the experi-
mental setup described (available at: http://github.com/
KHP-Informatics/PRQ). We named the script Preprocessing
for Relative Quantification of LC-MS/MS data (PRQ; see
Supplemental Methods–PRQ, available online). PRQ (1)
performs median ratio normalization [35], (2) calculates ra-
tios for each peptide, (3) derives protein level data from pep-
tide scores, and (4) collects the protein scores across all
TMT6Plexs.2.7. UCSF Memory and Aging Center cohort
2.7.1. Replication cohort: assessments, blood collection,
and processing
The replication cohort consisted of samples from 79 par-
ticipants enrolled in the UCSF Alzheimer’s Disease
Research Center (Table 1). All subjects underwent APOE
Table 1
Demographics of selected subjects from AIBL and UCSF cohorts
Variable
AIBL discovery cohort UCSF replication cohort
Low neocortical
SUVR (PiB2)
High neocortical
SUVR (PiB1) P value
Low neocortical
visual PiB read (PiB2)
High neocortical visual
PiB read (PiB1) P value
Subjects (n) 38 40 47 32
SUVR (missing) 1.11 6 0.06 2.34 6 0.33 2.4! 10225 1.2 6 0.12 (1) 2.2 6 0.35 (2) 4.2! 10216
Female gender 18 (47) 20 (50) .83 18 (38) 14 (44) .65
Age (y) 75.8 6 6.53 80.9 6 8.22 .0035 65 6 8.8 64 6 8.4 .61
Clinical diagnosis .0037 1.9! 10210
HC 13 (34) 6 (15) 2 (4.3) 1 (3.1)
SMC 18 (47) 13 (40) 1 (2.1) 1 (3.1)
MCI 7 (19) 16 (30) 0 (0) 0 (0)
AD 0 (0) 6 (15) 2 (4.3) 23 (72)
FTD 0 (0) 0 (0) 42 (89.3) 7 (21.8)
APOE ε4 carrier 14 (37) 25 (63) .36 8 (17) 13 (41) .036
MMSE 28.3 6 1.8 26.8 6 4.1 .038 26 6 4.3 21 6 6.9 .0011
Abbreviations: AD, Alzheimer’s disease; AIBL, Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing; APOE, apolipoprotein E; FTD,
frontotemporal dementia; HC, healthy control; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; PiB, Pittsburgh compound B;
SUVR, standardized uptake value ratio; UCSF, University of California San Francisco.
NOTE. Data presented as mean 6 standard deviation or n (%).
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plasma collection and storage [36], as previously described.
AD, frontotemporal dementia, and mild cognitive impair-
ment were diagnosed clinically by consensus applying stan-
dard research criteria [37–39]. All subjects underwent
PiB-PET at Lawrence Berkeley National Laboratory on a
Siemens ECAT EXACTHR PET (n5 69) or Biograph True-
point 6 PET/computed tomography (n5 10) [13]. The scans
were visually rated as PiB1 or PiB2 by an experienced sin-
gle rater, who was unaware of the clinical and plasma data
[13]. The mean 50- to 70-minute SUVR values were ex-
tracted from the frontal, parietal, cingulate, and lateral tem-
poral cortex, using the mean activity in the cerebellar gray
matter as the reference tissue (for details of image process-
ing, see Lehmann et al. [40]).
2.7.2. Immunoassay–enzyme-linked immunosorbent assay
Single analyte sandwich enzyme-linked immunosorbent
assay (ELISA) was used to quantify the candidate proteins
and were performed as per the manufacturer’s instructions
(see Supplemental Methods 6, available online).2.8. Statistical analysis
All statistical analyses were performed in R (see
Supplemental Methods 7, available online). For logistic
and linear regression analysis, age, gender, and the presence
of an APOE ε4 allele were used as covariates. For the ELISA
analysis, data outliers were excluded (63 standard devia-
tions) and a fourth covariate, batch, was added. The PET
scanner type was added as a covariate for the UCSF data.
Benjamini-Hochberg q values were calculated as a multiple
testing correction. Details of the pathway, regression, and
classification analyses are given in Supplemental Methods
7 (available online).3. Results
3.1. LC-MS/MS performed on AIBL subjects
LC-MS/MS was performed on plasma samples from 78
AIBL subjects, whose demographic data are listed in
Table 1. Combining the data from all MS/MS runs, we iden-
tified 4518 unique peptides sequences that corresponded to
789 unique protein groups. PRQ was able to extract 2319
unique TMT peptides, 1139 MW isoforms, and 379 unique
protein groups (see Supplemental Results 1a, available on-
line), which was reduced to 116 confidently annotated
unique protein groups after post-PRQ data clean up. This
consisted of 381 protein MW isoforms (see Supplemental
Results 1b, available online).3.2. Plasma protein markers of global PiB-PET
Each protein MW isoform underwent Mann-Whitney U
test and logistic regression analysis to compare PiB1 and
PiB2 groups and the Spearman rank correlation and linear
regression to associate the protein MW isoform levels
against PiB retention as a continuous measure. This was
completed for the mean and median protein roll-up methods
separately, giving a total of eight statistical tests per protein.
One protein MW isoform, complement C4a, passed all eight
statistical tests. A total of 69 protein MW isoforms passed at
least one statistical test (uncorrected P , .05; see
Supplemental Results 1c, available online). Pathway anal-
ysis (see Supplemental Results 2, available online) revealed
that these protein groups were overrepresented for involve-
ment in the complement and coagulation cascades
(P 5 3.7 ! 10222, q 5 3.3 ! 10221), systemic lupus
erythematosus (P5 2.65! 1024, q5 0.15), and prion dis-
eases (P 5 5.9! 1023, q 5 0.051). Three albumin and 15
immunoglobulin MW isoforms were removed, leaving 51
Table 2
LC-MS/MS data: Protein MW isoforms significantly associated with NAB
UniProt ID Protein name
1D-GE
fraction
Protein level data (roll up method indicated; i.e., mean or median)
Tests with
P , .05 (n)
Mean for all peptides mapping to protein Median over all peptides mappi to protein
Logistic
regression
Mann-Whitney
U test
Linear
regression
Spearman’s
rank correlation
Logistic
regression
Mann-Whitne
U test
Linear
regression
Spearman’s
rank correlation
b P value
Median
difference P value b P value r P value b P value
Median
difference P v ue b P value r P value
P0C0L4 Complement C4a 7 20.656 .038* 20.235 .027* 20.162 .019* 20.302 .007* 20.592 .049* 20.224 .03 20.143 .042* 20.229 .044* 8
P00738 Haptoglobin 8 20.932 .015* 20.331 .011* 20.170 .026* 20.248 .047* 21.048 .018* 20.190 .03 20.157 .043* 20.226 .070 7
P02647 Apolipoprotein A-I 10 20.877 .014* 20.173 .070 20.211 .013 20.204 .136 20.872 .025* 20.087 .08 20.183 .035* 20.266 .049* 5
O14791 Apolipoprotein L-1 5 0.829 .048* 0.731 .004* 0.165 .035* 0.308 .014* 0.578 .091 0.795 .00 0.120 .145 0.238 .061 5
P00738 Haptoglobin 5 20.728 .023* 20.521 .017* 20.198 .005* 20.280 .013* 20.446 .109 20.367 .13 20.149 .041* 20.181 .112 5
Q03591 FHR-1 8 1.667 .120 0.313 .008* 0.155 .178 0.483 .007* 1.414 .187 0.186 .01 0.144 .217 0.444 .014* 4
P25311 Zinc-a2-glycoprotein 7 0.140 .681 0.327 .043* 0.076 .461 0.327 .021* 0.140 .681 0.327 .04 0.076 .461 0.327 .021* 4
O43866 CD5 molecule like 5 20.929 .110 20.398 .013* 20.140 .088 20.288 .028* 20.596 .080 20.307 .01 20.165 .042* 20.235 .076 4
P04196 Histidine rich glycoprotein 5 20.996 .031* 20.093 .150 20.228 .011* 20.238 .096 20.996 .031* 20.093 .15 20.228 .011* 20.238 .096 4
P02747 C1q subcomponent subunit 2 20.746 .043* 20.460 .095 20.201 .024* 20.210 .165 20.746 .043* 20.460 .09 20.201 .024* 20.210 .165 4
P00450 Ceruloplasmin 6 22.088 .032* 20.222 .019* 20.105 .169 20.154 .247 22.088 .032* 20.222 .01 20.105 .169 20.154 .247 4
P04196 Histidine rich glycoprotein 3 1.205 .039* 0.334 .034* 0.120 .169 0.106 .449 1.149 .024* 0.611 .03 0.114 .199 0.084 .548 4
P00751 Complement factor B 1 0.341 .419 0.065 .657 0.164 .081 0.310 .038* 1.239 .371 0.058 .18 0.189 .042* 0.363 .014* 3
P04003 C4b-binding protein a chain 4 20.405 .189 20.108 .174 20.127 .076 20.248 .035 20.466 .106 20.473 .03 20.105 .154 20.275 .018* 3
P02647 Apolipoprotein A-I 6 20.487 .080 20.074 .310 20.157 .023* 20.189 .098 20.403 .137 20.156 .10 20.143 .038* 20.236 .038* 3
P02679 FGG 6 0.108 .789 20.038 .081 0.044 .613 20.331 .021* 20.671 .085 20.206 .16 20.191 .021* 20.298 .039* 3
Q92620 DEAH box protein 38 2 20.383 .351 0.046 .044* 20.095 .207 0.223 .067 20.380 .351 0.046 .03 20.095 .208 0.243 .046* 3
Q06033 ITI heavy chain H3 2 1.525 .027* 0.297 .099 0.148 .144 0.170 .265 1.267 .019* 0.422 .01 0.187 .061 0.225 .137 3
P06727 Apolipoprotein A-IV 6 21.837 .206 20.100 .087 20.144 .115 20.389 .010* 21.432 .271 20.093 .10 20.139 .128 20.387 .010* 2
O43866 CD5 molecule like 6 0.556 .275 0.277 .147 0.077 .400 0.347 .022* 0.260 .484 0.623 .20 0.090 .313 0.369 .015* 2
P08603 Complement factor H 6 0.031 .917 0.147 .409 20.001 .989 0.128 .299 0.190 .490 0.243 .04 20.001 .987 0.286 .018* 2
P01023 a2m 3 0.046 .853 0.331 .130 0.048 .497 0.290 .010* 0.034 .893 0.351 .22 0.042 .559 0.254 .025* 2
P07357 Complement C8 a chain 5 20.303 .346 20.294 .111 20.105 .229 20.197 .137 20.539 .104 20.474 .03 20.153 .073 20.261 .048* 2
P00739 Haptoglobin-related protein 5 0.960 .076 0.190 .072 0.209 .016* 0.232 .104 0.960 .076 0.190 .07 0.209 .016* 0.232 .104 2
P08519 Apolipoprotein(a) 1 0.929 .062 0.315 .030* 0.115 .212 0.237 .105 0.869 .064 0.222 .04 0.111 .226 0.221 .131 2
P04003 C4b-binding protein a chain 7 20.602 .064 20.198 .238 20.153 .028* 20.156 .173 20.648 .052 20.199 .15 20.158 .023* 20.150 .189 2
P19823 ITI heavy chain H2 4 20.762 .067 20.294 .026* 20.159 .061 20.267 .039* 20.510 .105 20.412 .12 20.134 .112 20.158 .227 2
P01024 Complement C3 6 20.374 .171 0.034 .783 20.148 .035* 20.107 .351 20.445 .116 20.115 .47 20.156 .025* 20.119 .300 2
Q92620 DEAH box protein 38 5 0.449 .199 0.123 .576 0.197 .038* 0.144 .318 0.449 .199 0.123 .57 0.197 .038* 0.144 .318 2
Q14624 ITI heavy chain H4 1 1.244 .041* 0.187 .118 0.251 .013* 0.222 .142 0.651 .220 0.127 .28 0.152 .139 0.136 .373 2
P00747 Plasminogen 1 0.901 .026* 0.610 .078 0.151 .112 0.154 .295 0.786 .049* 0.409 .10 0.128 .182 0.119 .420 2
P06396 Gelsolin 5 1.018 .251 0.174 .033* 0.095 .275 0.171 .198 1.149 .202 0.151 .04 0.095 .275 0.088 .509 2
P01023 a2m 9 20.749 .035* 20.246 .112 20.196 .037* 20.092 .482 20.555 .078 20.165 .23 20.139 .113 20.044 .737 2
O75636 Ficolin-3 6 20.372 .249 0.043 .629 20.152 .044* 0.034 .798 20.372 .249 0.043 .62 20.152 .044* 0.034 .798 2
P19827 ITI heavy chain H4 8 20.396 .253 20.252 .301 20.155 .115 20.265 .069 20.337 .373 20.196 .28 20.164 .113 20.313 .030* 1
P01023 a2m 2 20.044 .861 20.190 .823 0.000 .996 0.013 .912 0.108 .659 0.259 .17 0.048 .495 0.237 .037 1
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Table 2
LC-MS/MS data: Protein MW isoforms significantly associated with NAB (Continued )
UniProt ID Protein name
1D-GE
fraction
Protein level data (roll up method indicated; i.e., mean or median)
Tests with
P , .05 (n)
Mean for all peptides mapping to protein Median over all peptides mapping to protein
Logistic
regression
Mann-Whitney
U test
Linear
regression
Spearman’s
rank correlation
Logistic
regression
Mann-Whitney
U test
Linear
regression
Spearman’s
rank correlation
b P value
Median
difference P value b P value r P value b P value
Median
difference P value b P value r P value
P02790 Hemopexin 5 0.255 .341 0.018 .368 0.080 .252 0.152 .184 0.424 .158 0.164 .123 0.105 .134 0.228 .045* 1
P01023 a2m 1 0.325 .196 0.198 .133 0.057 .420 0.118 .303 0.340 .181 0.469 .046* 0.063 .380 0.184 .107 1
P13671 Complement C6 2 20.454 .132 20.338 .064 20.089 .288 20.167 .190 20.430 .145 20.662 .048* 20.085 .310 20.203 .110 1
P02675 Fibrinogen b chain 6 20.441 .241 0.042 .869 20.113 .117 20.082 .504 20.539 .090 20.213 .341 20.172 .016* 20.188 .125 1
P02790 Hemopexin 6 0.587 .049* 0.216 .053 0.090 .203 0.230 .059 0.429 .147 0.234 .082 0.041 .562 0.166 .176 1
P01024 Complement C3 8 20.569 .058 20.480 .030* 20.129 .101 20.166 .161 20.422 .132 20.401 .081 20.091 .249 20.135 .255 1
P02787 Serotransferrin 1 0.123 .658 0.205 .170 0.046 .544 0.093 .450 0.249 .372 0.352 .040* 0.068 .370 0.133 .281 1
P02647 Apolipoprotein A-I 5 20.458 .221 20.293 .126 20.101 .229 20.263 .046* 20.237 .484 20.099 .333 20.026 .762 20.129 .335 1
P0C0L4 Complement C4a 1 0.735 .117 0.058 .937 0.241 .009* 0.160 .293 0.156 .631 20.004 .847 0.064 .513 0.124 .419 1
P02647 Apolipoprotein A-I 9 20.599 .039* 20.061 .255 20.134 .060 20.033 .780 20.414 .134 0.036 .812 20.090 .211 0.067 .566 1
P00450 Ceruloplasmin 2 0.543 .136 20.097 .638 0.167 .029* 0.000 .998 0.177 .524 0.038 .946 0.082 .302 0.058 .639 1
P00734 Prothrombin 6 1.356 .402 0.004 .409 0.190 .027* 0.208 .135 20.053 .879 20.001 .908 20.002 .983 0.056 .689 1
P10909 Clusterin 6 20.480 .134 0.036 .422 20.159 .037* 20.102 .408 20.434 .179 20.150 .646 20.140 .068 20.033 .789 1
P02671 Fibrinogen a chain 4 20.698 .122 20.175 .107 20.142 .052 20.284 .012* 20.054 .835 0.065 .700 20.054 .472 20.028 .809 1
P04196 Histidine rich glycoprotein 6 20.459 .343 0.005 .447 20.185 .049* 20.194 .214 20.315 .485 0.251 .895 20.163 .083 20.021 .895 1
Abbreviations: 1D-GE, one-dimensional gel electrophoresis; a2m, a2-macroglobulin; FGG, fibrinogen g-chain; FHR-1, factor H-related protein 1; ID, identification; ITI, inter-a-trypsin inhibitor; LC-MS/MS,
liquid chromatography tandem mass spectrometry; UniProt, Universal Protein Resource.
NOTE. All multiple testing corrected q values were .0.75; for regression analysis, age, gender, and presence of apolipoprotein E ε4 were used as covariates.
*Statistically significant.
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Fig. 1. Flow diagram to select liquid chromatography tandem mass spectrometry plasma neocortical amyloid burden (NAB) candidate markers for technical
replication. *Two protein molecular weight (MW) isoforms associated with NAB; **three protein MW isoforms associated with NAB; ***four protein MW
isoforms. Abbreviations: Ab, amyloid b; a2m, a2-macrohpage; FGG, fibrinogen g-chain; FHR-1, factor H-related protein 1.
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(Table 2).
Subsequently, 17 proteins were selected for technical
replication (Fig. 1). In addition to the statistical evidence,
we also considered the candidate’s relationship with the am-
yloid and/or AD Genome-Wide Association Studies results
(see Supplemental Results 3, available online). We also
chose to replicate histidine-rich glycoprotein, the protein
most associated with NAB, but that had no previous evi-
dence for a relationship with Ab.3.3. Technical replication
We sought to translate our discovery findings to a simple-
to-use commercially available ELISA format. The 17 pro-
tein candidates from MS were measured in plasma samples
from the 78 AIBL subjects in the discovery cohort. Usinglinear regression models (including age, gender, APOE ε4,
and ELISA plate as covariates), we found that two proteins,
a2-macroglobulin (a2m) (q5 0.076) and fibrinogen g-chain
(FGG) (q5 0.076), replicated our findings from the LC-MS/
MS discovery study (Table 3). In the discovery study, factor
H-related protein 1 (FHR-1) was increased in the
PiB1 group. Although FHR-1 (q 5 0.076) was associated
with NAB at the 0.1 q value in the ELISA technical replica-
tion, an opposite trend was observed. Apolipoprotein A-IV,
gelsolin, histidine-rich glycoprotein, haptoglobin, and apoli-
poprotein(a) all showed the same directional change as in the
LC-MS/MS discovery.3.4. Independent replication
To verify the results from the AIBL samples, we
measured the levels of the three proteins significantly
Table 3
Technical replication of plasma protein candidates discovered by LC-MS/MS
UniProt ID Protein name Outliers excluded (n)
Logistic regression with SUVR .1.3 Linear regression with SUVR
b P value q value b P value q value
P01023 a2m 10 1 8.9! 1023 0.076 0.2 7.9! 1023 0.068
Q03591 FHR-1 11 21 4.6! 1023 0.076 20.22 5.5! 1023 0.068
P02679 FGG 0 20.7 .041 0.23 20.2 .014 0.081
P08519 Apolipoprotein(a) 21 0.48 .13 0.34 0.18 .042 0.18
P06396 Gelsolin 2 20.48 .11 0.34 20.14 .068 0.19
P00738 Haptoglobin 2 20.38 .18 0.39 20.13 .089 0.19
P04196 Histidine rich glycoprotein 2 0.48 .14 0.34 0.14 .081 0.19
P06727 Apolipoprotein A-IV 2 20.63 .083 0.34 20.17 .067 0.19
P01024 Complement C3 0 20.61 .25 0.47 20.21 .13 0.25
P0C0L4 Complement C4a 0 20.55 .51 0.66 20.27 .22 0.38
P10909 Clusterin 0 20.27 .36 0.51 20.091 .27 0.41
P02647 Apolipoprotein A-I 0 0.34 .29 0.47 0.088 .32 0.46
P02671 Fibrinogen a chain 6 20.28 .3 0.47 20.064 .39 0.52
P02787 Serotransferrin 1 20.013 .96 0.96 20.041 .6 0.73
O14791 Apolipoprotein L-1 0 20.09 .74 0.89 20.026 .73 0.77
P08603 Complement factor H 3 0.066 .8 0.89 0.027 .7 0.77
P00751 Complement factor B 2 0.053 .84 0.89 0.018 .81 0.81
Abbreviations: 1D-GE, one-dimensional gel electrophoresis; a2m, a2-macroglobulin; FGG, fibrinogen g-chain; FHR-1, factor H-related protein 1; ID, iden-
tification; ITI, inter-a-trypsin inhibitor; LC-MS/MS, liquid chromatography tandem mass spectrometry; UniProt, Universal Protein Resource.
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ples from an independent cohort. These proteins were
measured using ELISA in 79 samples from the UCSF cohort
(Table 1). FGG was significantly associated with PiB posi-
tivity, as determined both by visual examination of PiB-
PET scans (q 5 5.9 ! 1023) and by applying a threshold
of 1.3 to SUVRs (q 5 0.051; Table 4). Despite not being
significantly associated with NAB, a2m correlated with
SUVR positivity in the same direction as in the discovery
study.3.5. Multivariate analysis
Subjects with any missing covariates or protein measure-
ments were excluded from the multivariate analysis, leaving
58 subjects from AIBL (28 PiB2, 30 PiB1 using an
SUVR .1.3) and 78 subjects from UCSF (46 PiB2, 32
PiB1 determined from visual inspection). Classification
models were trained in the AIBL ELISA data to predict
SUVR positivity (.1.3) and tested in the UCSF ELISATable 4
Independent replication of plasma protein candidates discovered by LC-MS/MS a
UniProt ID Protein name
Logistic regression to visual read
Log
.1.3
b P value q value b
P01023 a2m 20.013 .96 0.96 0.2
P02679 FGG 21.0 2.0! 1023 5.9! 1023 20.7
Q03591 FHR-1 20.066 .79 0.96 0.0
Abbreviations: a2m, a2-macroglobulin; FGG, fibrinogen g-chain; FHR-1, factor
tandem mass spectrometry; SUVR, standardized uptake value ratio; UniProt, Uni
NOTE. Only one outlier (.3 standard deviations from mean) was excluded, wh
apolipoprotein E ε4, enzyme-linked immunosorbent assay plate, and scanner typedata to predict PiB positivity, determined by visual inspec-
tion (more robust across multiple scanners). A “basic”
model (age, gender, APOE ε4) was compared with a
“basic 1 protein” model, which also used the plasma con-
centration of FGG, a2m, and FHR-1. Fig. 2A and 2B shows
a receiver operating characteristic analysis, in which area
under the curve (AUC) was shown to be greater for the
“basic 1 protein” model than for the “basic” model in the
test data sets. The highest test AUC was found using the
random forest approach, in which the basic1 protein model
(AUC 0.70) outperformed the basic model (AUC5 0.46) in
the test data set. The random forest basic 1 protein model
gave a test set sensitivity of 50% and specificity of 85%.
Additionally, a classification tree was fitted to the
basic 1 protein model to provide a simpler alternative
with clear thresholds. The resulting classification tree used
just two variables (age/plasma FGG level; Fig. 2C) and
achieved a comparable AUC to that of the random forest
model (AUC 0.69, sensitivity 59%, specificity 78%). In the
UCSF cohort, 23 of 25 AD subjects were PiB1, and twond technically replicated
istic regression to SUVR
Linear regression to SUVR
P value q value b P value q value
7 .29 0.44 0.075 .22 0.33
4 .017 0.051 20.21 4.1! 1024 1.2! 1023
11 .97 0.97 1.5! 1023 .98 0.98
H-related protein 1; ID, identification; LC-MS/MS, liquid chromatography-
versal Protein Resource.
ich was detected for FGG; for regression analysis, age, gender, presence of
were used as covariates.
Fig. 2. Receiver operating characteristic (ROC) curves for the prediction of Pittsburgh compound B (PiB) positivity. A “basic” model (age, gender, APOE ε4
presence) was compared with a “basic1 protein” model that also included the plasma levels of fibrinogen g-chain (FGG), a2-macrophage, and factor H-related
protein 1. Random forest (RF) and classification and regression trees (CARTs) were used to fit models in classification and regression training using default
parameters. The area under the curve (AUC) is given for each model. ROC curves are shown comparing the predictive accuracy of the models in (A) the training
data set (Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing [AIBL]) and (B) the test data set (University of California, San Francisco).
Classification tree trained on AIBL enzyme-linked immunosorbent assay data to predict neocortical amyloid burden positivity and estimated cutoff (C).
N.J. Ashton et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 48–6056PiB2 subjects had plasma FGG levels greater than the
threshold (see Supplemental Results 4, available online).4. Discussion
With the failure of serial amyloid-based therapeutic
agents in clinical trials compromised by the inclusion of sub-
stantial numbers of participants without the target pathologic
entity [18], and with the prospect of very large trials in pre-symptomatic AD such as the A4 trial and others [5], the need
for blood-based markers of NAB has never been greater.
Blood-based biomarkers could be used to screen large
numbers of potential participants, and only those predicted
to have abnormally high NAB would be retested using cere-
brospinal fluid assays or PET scans, reducing the screen fail-
ure rates. This could reduce recruitment time and costs and
allow eligible subjects to be identified more readily (e.g.,
from biobanks with permission for recontact).
N.J. Ashton et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 48–60 57The present study has demonstrated that a simple blood
test consisting of FGG plasma levels and patient age could
have some potential for predicting NAB, achieving a test
set sensitivity, specificity, and AUC of 59%, 78%, and
69% respectively, highlighting its potential use in strati-
fying patients for anti-amyloid trials. This independent
replication was performed in a mixed dementia cohort
(UCSF), suggesting that FGG and age could also have util-
ity for distinguishing between amyloid and nonamyloid
dementias. Additionally, because the classification model
was trained in a subset of the AIBL cohort containing
very few AD subjects, it is more likely that FGG will be
able to predict PiB positivity in non-AD subjects. Howev-
er, because the UCSF cohort contained only two cogni-
tively normal individuals, additional work is needed to
determine the sensitivity and specificity in those who are
cognitively normal. These measures will determine the
cost-saving potential of this blood test for prevention tri-
als. Preliminary data generated from a cognitively normal
cohort in our laboratory supports this (data not shown).
Previously, Burnham et al. [31] reported a blood test that
achieved 79% sensitivity and 76% specificity in an inde-
pendent test set. Although our sensitivity was slightly
lower, this was achieved by measuring a single plasma
protein compared with the 6 plasma proteins used in the
Burnham model.
Although the sensitivity and specificity of these markers
for predicting NAB was not high enough to use clinically,
they would be useful for enrichment of clinical trials if they
performed at this level in relevant populations. The stron-
gest case can be made for prevention trials in asymptom-
atic subjects because of the large expected screen failure
rate (w66% or higher) when searching for individuals
with elevated NAB. Because of the relatively high cost
of amyloid-PET scans (w$3000) versus blood protein ELI-
SAs, even a blood test without clinical utility could theoret-
ically save millions of dollars for studies the size of A4
(n 5 1000).
TheAPOE ε4 allele is a substantial risk factor for AD [41]
and amyloid [30,42]. Although we considered APOE ε4
during our analyses, we were not surprised to find that the
APOE genotype markers did not improve our classification
model, because the study was designed to be independent
of this effect. However, in a general population sample, the
APOE genotype is likely to contribute to the prediction of
NAB.
It was interesting that FGG, and to a lesser extent com-
plement C3 and fibrinogen a-chain, were associated with
NAB in our study, which has been previously found
[29,30]. However, in the study by Burnham et al. [31], total
fibrinogen was not associated with NAB. In contrast, Kid-
dle et al. [30] showed that it was negatively associated with
NAB. Furthermore, decreased levels of plasma FGG have
been shown to be associated with a smaller whole brain
volume in AD subjects [26] and measures of whole fibrin-
ogen in plasma have shown an increase [43,44].Discrepancies in these findings might have resulted from
the platform used to measure total fibrinogen or might
highlight the importance of studying specific fibrinogen
chains.
FGG is normally rejected from the brain by the blood-
brain barrier (BBB), yet has still been detected in mice
and human brain tissue [45,46]. This could result from the
reported dysfunction of the BBB in mice [47] and humans
in AD [48]. However, the movement of fibrinogen across a
defected BBB seems to be molecule-specific, because
smaller molecules are not BBB permeable in AD [49].
Fibrinogen has been shown to accumulate over time as the
AD pathology progresses [46] and codeposits with Ab in
brain tissue [50]. Ahn et al. [51] demonstrated that fibrin-
ogen binds to Ab, which enhances aggregation and increases
Ab fibrillization. It is possible that the decreased FGG levels
associated with high NAB in our study resulted from move-
ment of fibrinogen across a compromised BBB in the sub-
jects with AD pathologic features.
After FGG, a2m was the second most promising candi-
date, shown for the first time to associate with NAB. This
is noteworthy, because a2m has been found to be one of
the most replicable markers of other AD-related phenotypes,
including diagnosis, hippocampal metabolism, and response
to treatment with divalproex sodium [20]. Future studies
should aim to replicate all previously discovered markers
of NAB and investigate which combination of analytes
would achieve greater sensitivity and specificity.
To our knowledge, this is the first study to apply an un-
biased and nontargeted quantitative LC-MS/MS discovery
approach, combining LC-MS/MS with TMT labeling, for
the investigation of plasma proteins related to NAB.
Furthermore, this method will allow the unprecedented
exploration of plasma peptide and modified proteins as
markers of NAB. We have also described a novel and auto-
mated bioinformatic pipeline, PRQ, to accurately prepro-
cess the TMT-MS data. PRQ not only conducts rigorous
normalization of MS data [35] but also automates the
calculation of peptide/protein ratios against the study refer-
ence.
Subsequently, technical replication was performed to
reduce the number of false-positive results and to ensure
translation of LC/MS-MS findings using a platform more
applicable to the clinical setting. Using commercially avail-
able immunoassays, we confirmed that a2m, FGG, and
FHR-1 significantly predicted NAB, with a 0.1 q-value sig-
nificance level. All except FHR-1 displayed a similar direc-
tion of association between discovery and replication.
Immunoassays cannot always distinguish between sequence
variants, proteins modified with different post-translational
modification, or different truncated forms of a same protein
seen by LC/MS-MS. This could also explain the differences
seen in the association trend between discovery and replica-
tion in some cases (e.g., FHR-1); therefore, these candidates
should not necessarily be discounted. The discrepancies
observed between the two platforms point to the need for
N.J. Ashton et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 48–6058investigation of protein modifications as potential bio-
markers in future studies.
The discrepancies between the findings from the AIBL
and UCSF studies could have resulted from the low statisti-
cal power, differences in disease stage, or differences in pre-
analytical factors. The major difference in the preanalytical
factors is the centrifugation step of plasma collection. AIBL
used a two-step centrifugation (200g, remove supernatant,
then 800g), and UCSF used a single centrifugation step
(1300–1800g). This highlights the importance of standardi-
zation of blood collection and preparation for biomarker
studies.
Although many have agreed that Ab deposition is the
earliest event in AD pathogenesis, one group has shown
changes in episodic memory preceding the changes in Ab
levels [52]. If confirmed in other cohorts, it would be inter-
esting to compare the ability of episodic memory and our
blood test to predict NAB in asymptomatic individuals.
In conclusion, the present study reports a potential
blood test, consisting of measuring FGG, which, along
with age, showed some ability to predict NAB in an inde-
pendent sample. To ensure the robustness and relevance of
these findings, this test must be replicated in larger cohorts
that are more representative of the relevant clinical trial
populations. Our results provide additional evidence that
differences in the plasma proteome in relation to AD
and its pathology do exist. Therefore, such changes could
be used to stratify patients for anti-amyloid treatment tri-
als. This could lower barriers to the development of an
effective treatment to combat the increasing concern of
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1. Systematic review: We searched PubMed up to June
2014 using the keywords, Alzheimer’s disease (AD),
plasma biomarkers, pathology, fibrinogen gamma
chain (FGG), beta amyloid.
2. Interpretation: Previous targeted studies have
demonstrated that the combination of several blood
proteins had the potential to predict the NAB. Our
study is the first to apply an unbiased and nontargeted
quantitative LC-MS/MS discovery approach, com-
bined with isobaric labeling, to investigate the
plasma proteins related to NAB. Our findings showed
a prediction of NAB, with comparable accuracy to
previous studies, which used a single plasma protein.
This highlights the potential use of a simple blood-
based screen to stratify patients for anti-amyloid
trials.
3. Future directions: To ensure the robustness and reli-
ability of these findings, this test should be replicated
in larger cohorts more representative of relevant clin-
ical trial populations.References
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